News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/scully-marie-240.jpg)
Caplacizumab improves outcomes in aTTP
- Author:
- Jen Smith
ATLANTA—Caplacizumab can improve outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP), according to research presented at...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/seymour-john-ASH2017-240.jpg)
Chemo-free combo should be option for rel/ref CLL, doc says
- Author:
- Jen Smith
ATLANTA—The combination of venetoclax and rituximab (VR) should be a standard treatment option for adults with relapsed/refractory chronic...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/raskob-gary-240.jpg)
Edoxaban noninferior to dalteparin for VTE in cancer
- Author:
- Jen Smith
ATLANTA—Edoxaban is noninferior to dalteparin for the treatment of cancer-associated venous thromboembolism (VTE), a phase 3 study suggests. In...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/mateos-maria-victoria-240.jpg)
Combo should be standard in MM, doc says
- Author:
- Jen Smith
ATLANTA—Study results “strongly support” a new standard of care for transplant-ineligible patients with newly diagnosed multiple myeloma (MM),...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ASH2017-credit-ASH-240.jpg)
Emicizumab reduces bleeds in kids with hemophilia A and inhibitors
- Author:
- Jen Smith
ATLANTA—Updated results from the HAVEN 2 trial have shown that emicizumab prophylaxis can reduce bleeds in children with hemophilia A and factor...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/DNA_repair_Credit_Tom_Ellenberger_230.jpg)
Team discovers oncogenic driver of T-ALL
- Author:
- Jen Smith
Preclinical research suggests the TOX protein is an oncogenic driver of T-cell acute lymphoblastic leukemia (T-ALL). Results indicate that TOX...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/pembrolizumab-keytruda-merck_230.jpg)
FDA warns about risk of death with pembrolizumab in MM
- Author:
- Jen Smith
The US Food and Drug Administration (FDA) has issued a statement warning about an increased risk of death associated with an unapproved use of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Polycythemia_vera_blood_smear_Credit_AFIP_230.jpg)
Methotrexate could treat myeloproliferative neoplasms
- Author:
- Jen Smith
Methotrexate (MTX) may be a feasible treatment option for myeloproliferative neoplasms (MPNs), according to preclinical research published in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg)
Drug receives orphan designation for ocular GVHD
- Author:
- Jen Smith
The US Food and Drug Administration (FDA) has granted orphan drug designation to OCU300 (brimonidine tartrate) for the treatment of ocular graft-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/multiple_myeloma_bone_marrow_aspirate_showing_230.jpg)
KRD appears more active, less safe than KCD in newly diagnosed MM
- Author:
- Jen Smith
MADRID—New research suggests one triplet regimen may be more active but also more toxic than another in patients with newly diagnosed multiple...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CLL_cells.jpg)
High ORR with sequential regimen in CLL
- Author:
- Jen Smith
LUGANO, SWITZERLAND—A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/wei-andrew-eha2017-240.jpg)
Combo may be option for elderly patients with untreated AML
- Author:
- Jen Smith
MADRID—The combination of venetoclax and low-dose cytarabine (VEN+LDAC) appears to be a feasible treatment option for elderly patients with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/14-icml-attendees-230.png)
GAD-M produces high ORR in treatment-naïve ENKTL
- Author:
- Jen Smith
LUGANO, SWITZERLAND—A 4-drug regimen has demonstrated efficacy in a phase 2 trial of patients with treatment-naïve extranodal natural killer/T-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/salles-gilles-240-rev.jpg)
CTL019 produces responses in rel/ref DLBCL
- Author:
- Jen Smith
The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CLL_cells.jpg)
Combo demonstrates activity in CLL/SLL and FL
- Author:
- Jen Smith
LUGANO, SWITZERLAND—Results of a phase 1 study suggest a 2-drug combination may be safe and effective in patients with chronic lymphocytic...